Neurocrine Biosciences Inc (NBIX.O): Crenessity Growth Continues to Outpace Expectations While Ingrezza Guide Raise Reinforces Durable VMAT2 Demand-20260731
神经分泌生物科学(US:NBIX) 花旗·2026-07-31 11:17Flash | 30 Jul 2026 22:02:49 ET │ 11 pages Neurocrine Biosciences Inc (NBIX.O) Crenessity Growth Continues to Outpace Expectations While Ingrezza Guide Raise Reinforces Durable VMAT2 Demand CITI'S TAKE Buy / High Risk | Price (30 Jul 26 16:00) | US$185.50 | | --- | --- | | Target price | US$246.00 | | Expected share price return | 32.6% | | Expected dividend yield | 0.0% | | Expected total return | 32.6% | | Market Cap | US$18,652M | Yigal Nochomovitz, Ph.D.AC +1-212-816-1441 yigal.nochomovitz@citi.com NBIX ...